Prostate Size as a Predictor of Gleason Score Upgrading in Patients With Low Risk Prostate Cancer
Judson D. Davies(Vanderbilt University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center), Shady Salem(Vanderbilt University Medical Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), S. Duke Herrell(Vanderbilt University Medical Center), Peter E. Clark(Levine Cancer Institute), Sharon Phillips(Vanderbilt University Medical Center), Joseph A. Smith(King's College London), Monty Aghazadeh(Vanderbilt University Medical Center), Sam S. Chang(Vanderbilt University), Rodney Davis(The University of Texas MD Anderson Cancer Center)
Cited by 63
Related Papers
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
|New England Journal of Medicine|2003|2k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845